報價延遲最少15分鐘:2025/06/01 00:30 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.23 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.97/-2.66
|
|
企業價值
145.12M
|
| 資產負債 |
|
每股賬面淨值
0.56
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 00:30 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. |